MA31162B1 - Préparation pharmaceutique pour soulager l'endométriose - Google Patents

Préparation pharmaceutique pour soulager l'endométriose

Info

Publication number
MA31162B1
MA31162B1 MA32138A MA32138A MA31162B1 MA 31162 B1 MA31162 B1 MA 31162B1 MA 32138 A MA32138 A MA 32138A MA 32138 A MA32138 A MA 32138A MA 31162 B1 MA31162 B1 MA 31162B1
Authority
MA
Morocco
Prior art keywords
pharmaceutical composition
bone density
dilution
endometriosis
uterine lining
Prior art date
Application number
MA32138A
Other languages
Arabic (ar)
English (en)
Inventor
Christian Seitz
Annemarie Wasserfall
Holger Zimmermann
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of MA31162B1 publication Critical patent/MA31162B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une composition pharmaceutique conçue pour traiter une endométriose sans réduire la densité osseuse. Cette composition contient un gestagène anti-androgène, de préférence 17a-cyanométhyl-17-ß-hydroxyestra-4,9-dièn-3one (dienogest), acétate de cyprotérone ou acétate de chlormadinone, dans une dose journalière qui est au maximum deux fois supérieure à la dose d'inhibition d'ovulation, avec un ou plusieurs adjuvants/supports pharmaceutiquement acceptables. La composition pharmaceutique selon cette invention permet de traiter une endométriose sans influencer négativement le métabolisme osseux, ni la densité osseuse, et permet en même temps de maintenir à un niveau acceptable les effets secondaires connus (par ex. Bouffées de chaleur, acné, influence négative sur le profil lipidique) engendrés par les médicaments classiques. Ladite composition pharmaceutique est par conséquent adaptée à une application à long terme.
MA32138A 2007-03-01 2009-08-04 Préparation pharmaceutique pour soulager l'endométriose MA31162B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07004202A EP1977752A1 (fr) 2007-03-01 2007-03-01 Composition pharmaceutique destinée à réduire l'endométriose
PCT/EP2008/001451 WO2008104342A1 (fr) 2007-03-01 2008-02-23 Préparation pharmaceutique conçue pour traiter une endométriose

Publications (1)

Publication Number Publication Date
MA31162B1 true MA31162B1 (fr) 2010-02-01

Family

ID=38045772

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32138A MA31162B1 (fr) 2007-03-01 2009-08-04 Préparation pharmaceutique pour soulager l'endométriose

Country Status (18)

Country Link
EP (2) EP1977752A1 (fr)
JP (1) JP2010520159A (fr)
KR (1) KR20090119829A (fr)
CN (1) CN101583364A (fr)
AU (1) AU2008221012A1 (fr)
BR (1) BRPI0806598A2 (fr)
CA (1) CA2673936A1 (fr)
CO (1) CO6190606A2 (fr)
CR (1) CR10912A (fr)
DO (1) DOP2009000171A (fr)
EA (1) EA200900829A1 (fr)
EC (1) ECSP099482A (fr)
MA (1) MA31162B1 (fr)
MX (1) MX2009007259A (fr)
NZ (1) NZ577761A (fr)
SV (1) SV2009003324A (fr)
TN (1) TN2009000263A1 (fr)
WO (1) WO2008104342A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101874806A (zh) * 2009-04-29 2010-11-03 北京本草天源药物研究院 一种地诺孕素固体制剂
CN102670519B (zh) * 2011-03-16 2014-06-11 重庆莱美药业股份有限公司 一种可快速溶出的地诺孕素口服制剂及其制备方法
CN103304619B (zh) * 2013-06-08 2015-12-02 西藏海思科药业集团股份有限公司 一种地诺孕素化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4426601A1 (de) * 1994-07-27 1996-02-01 Schering Ag Verwendung eines Kombinationsproduktes enthaltend einen kompetitiven Progesteronantagonisten und ein Gestagen zur Herstellung eines Arzneimittels zur Behandlung der Endometriose oder des Leiomyomata uteri
EP1535618A1 (fr) * 2003-11-26 2005-06-01 Schering Aktiengesellschaft Préparation pharmaceutique pour le traitement hormonal continuel sur plus de 21-28 jours comprenant deux compositions d'estrogène et/ou de progestine
MY151322A (en) * 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
DE102004026679A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat
EP1655031A1 (fr) * 2004-10-08 2006-05-10 Schering AG Utilisation de dienogest pour contraceptives hormonelles avec cycle prolongué

Also Published As

Publication number Publication date
EP2059248A1 (fr) 2009-05-20
NZ577761A (en) 2012-03-30
ECSP099482A (es) 2009-08-28
AU2008221012A1 (en) 2008-09-04
CA2673936A1 (fr) 2008-09-04
TN2009000263A1 (en) 2010-10-18
EP1977752A1 (fr) 2008-10-08
CN101583364A (zh) 2009-11-18
DOP2009000171A (es) 2009-08-31
CR10912A (es) 2009-08-13
JP2010520159A (ja) 2010-06-10
CO6190606A2 (es) 2010-08-19
SV2009003324A (es) 2009-10-02
MX2009007259A (es) 2009-07-10
WO2008104342A1 (fr) 2008-09-04
EA200900829A1 (ru) 2010-02-26
KR20090119829A (ko) 2009-11-20
BRPI0806598A2 (pt) 2014-05-06

Similar Documents

Publication Publication Date Title
Schattenberg et al. A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA
Kim et al. Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function
Zelander Ultrastructure of the mouse adrenal cortex: an electron microscopical study in intact and hydrocortisone-treated male adults
Tipoe et al. Epigallocatechin-3-gallate (EGCG) reduces liver inflammation, oxidative stress and fibrosis in carbon tetrachloride (CCl4)-induced liver injury in mice
FI3140393T3 (fi) Menetelmä aikuisen maksan esisolujen tuottamiseksi
Docherty et al. The role of sex in the pathophysiology of pulmonary hypertension
MA31162B1 (fr) Préparation pharmaceutique pour soulager l'endométriose
Suyavaran et al. TNF-α suppression by glutathione preconditioning attenuates hepatic ischemia reperfusion injury in young and aged rats
Kim et al. Sorafenib dose escalation in the treatment of advanced hepatocellular carcinoma
Jirouskova et al. Plectin controls biliary tree architecture and stability in cholestasis
Zhang et al. A new approach for Alzheimer's disease treatment through P-gp regulation via ibuprofen
van Golen et al. The pathophysiology of human obstructive cholestasis is mimicked in cholestatic Gold Syrian hamsters
Loughlin Calcium channel blockers and prostate cancer
Cardoso et al. The P2Y1 receptor-mediated leukocyte adhesion to endothelial cells is inhibited by melatonin
Gomez-Lechon et al. The immunosuppressant drug FK506 prevents Fas-induced apoptosis in human hepatocytes
Wong et al. Post exposure administration of A1 adenosine receptor agonists attenuates noise-induced hearing loss
Parés Treatment of primary biliary cirrhosis: Is there more to offer than ursodeoxycholic acid?
Kim et al. Celecoxib enhances the radiosensitizing effect of 7-hydroxystaurosporine (UCN-01) in human lung cancer cell lines
Jensen et al. Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemia
Russell et al. Adjuvant bisphosphonate treatment for breast cancer: Where are we heading and can the pre-clinical literature help us get there?
Ozdil et al. New therapeutic option with N-acetylcysteine for primary sclerosing cholangitis: two case reports
Ceresa et al. Bortezomib induces schedule-dependent modulation of gemcitabine pharmacokinetics and pharmacodynamics in non-small cell lung cancer and blood mononuclear cells
Mathurin et al. Treatment of severe forms of alcoholic hepatitis: where are we going?
Singh et al. Sanguinarine downregulates AT1a gene expression in a hypertensive rat model
Agarwal et al. Can subepididymal orchiectomy Re-emerge as the treatment of choice in patients with advanced prostatic carcinoma?